A new study by researchers at the Case Western Reserve University School of Medicine reveals that the popular diabetes and weight-loss drugs Wegovy and Ozempic are linked to reduced incidence and recurrence of alcohol abuse or dependence.
The team’s findings, recently published in the journal Nature Communications, may suggest a possible new treatment for excessive alcohol use—including alcohol-use disorder (AUD), a health condition that causes about 178,000 deaths in the United States each year, according to the Centers for Disease Control.
To date, the U.S. Food and Drug Administration (FDA) has approved only three medications to treat AUD.
The active ingredient in Wegovy and Ozempic is semaglutide, which belongs to a class of medications known as glucagon-like peptide-1 receptor agonists (GLP-1). GLP-1 helps regulate blood sugar in type 2 diabetes and reduces appetite.
The researchers examined electronic health records of nearly 84,000 patients with obesity. They found those treated with semaglutide, compared to those treated with other anti-obesity medications, showed a 50% to 56% decrease for both the initiation and re-occurrence of alcohol-use disorder in the year following.
“This is very promising news in that we may have a new therapeutic method to treat AUD,” said Rong Xu, a professor of biomedical informatics at the School of Medicine and the study’s lead researcher.
Xu, also director of the medical school’s Center for AI in Drug Discovery, was joined by medical school co-authors Nathan Berger, the Hanna-Payne Professor of Experimental Medicine, and Pamela Davis, the Arline H. and Curtis F. Garvin Research Professor. Nora D. Volkow, director of the National Institute on Drug Abuse, also co-authored the study.
“We collected real-world evidence in a manner similar to our previous two studies reported earlier this year,” Berger said. “In January we showed that semaglutide is associated with a decrease in suicidal thoughts, and in March, we demonstrated that semaglutide is also associated with a reduction in both new diagnoses and recurrence of cannabis-use disorder.”
Similar findings were replicated when the team examined electronic health records for about 600,000 patients with type 2 diabetes. Again, they found consistent reductions in alcohol-use disorder diagnoses among those treated with semaglutide.
“While the findings are promising and provide preliminary evidence of the potential benefit of semaglutide in AUD in real-world populations,” Davis said, “further randomized clinical trials are needed to support its use clinically for AUD.”
Research reported in this press release was supported by the National Institute on Alcohol Abuse and Alcoholism, National Institute on Aging, and National Cancer Institute, all of the National Institutes of Health, under award numbers AA029831, AG057557, AG061388, AG062272, AG07664, CA221718, CA043703, and CA2332216. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
For more information please contact Patty Zamora at patty.zamora@case.edu.